Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Robert Zeiser, PhD, Nicola Polverelli, MD PhD, Ron Ram, MD, Shahrukh K. Hashmi, MDMPH, Ronjon Chakraverty, BMBS, PhD, Mary E. D. Flowers, MD, Fitzroy Dawkins, MD, Norbert Hollaender, MD, Maanasa Gowda, PharmD, Tommaso Stefanelli, MD, Stephanie J. Lee, MDMPH, Takanori Teshima, MD, Franco Locatelli, MD PhD

Blood (2020) 136 (Supplement 1): 22–24.

https://doi.org/10.1182/blood-2020-137694

Published: 2020

Journal Articles

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Madan Jagasia, MD MS, Miguel-Angel Perales, MD, Mark A Schroeder, MD, Haris Ali, MD, Nirav N Shah, MD, Yi-Bin Chen, MD, Michael C. Arbushites, Fitzroy Dawkins, MD, Chuan Tian, PhD, Hanna Jean Khoury, MD FACP

Blood (2018) 132 (Supplement 1): 601.

https://doi.org/10.1182/blood-2018-99-116342

Published: 2018

Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD

Blood (2016) 128 (22): 4195.

https://doi.org/10.1182/blood.V128.22.4195.4195

Published: 2016

Journal Articles

Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.

Daniel Shasha, MD, Fitzroy Dawkins, MD, Donghan Luo, PhD, Francois E. Wilhelm, MD, PhD, MSc, Marc Kamin, MD

Blood (2007) 110 (11): 3775.

https://doi.org/10.1182/blood.V110.11.3775.3775

Published: 2007

Journal Articles

Epoetin alfa 80,000 U Every Three Weeks (Q3W) in Anemic Cancer Patients (pts) Not Receiving Chemotherapy (CT) or Radiation Therapy (RT).

Daniel Shasha, MD, Fitzroy Dawkins, MD, Francois E. Wilhelm, MD,PhD,MSc

Blood (2006) 108 (11): 3755.

https://doi.org/10.1182/blood.V108.11.3755.3755

Published: 2006

Journal Articles

Cancer Incidence in Sickle Cell Disease. Howard University, 1996–2004.

Fitzroy Dawkins, MD, Hilary Ufearo, MD, Jeremy Pantin, MD, John Kwagyan, PhD, Catherine Nwokolo, RN, Onyinye C. Onyekwere, MD, Victor R. Gordeuk, MD, Oswaldo Castro, MD

Blood (2005) 106 (11): 3788.

https://doi.org/10.1182/blood.V106.11.3788.3788

Published: 2005

NARROW

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.

Epoetin alfa 80,000 U Every Three Weeks (Q3W) in Anemic Cancer Patients (pts) Not Receiving Chemotherapy (CT) or Radiation Therapy (RT).

Cancer Incidence in Sickle Cell Disease. Howard University, 1996–2004.

Email alerts

ASH Publications

American Society of Hematology

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.

Epoetin alfa 80,000 U Every Three Weeks (Q3W) in Anemic Cancer Patients (pts) Not Receiving Chemotherapy (CT) or Radiation Therapy (RT).

Cancer Incidence in Sickle Cell Disease. Howard University, 1996–2004.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only